About This Fund
LYFE Capital Fund IV (Dragon) L.P. is the fourth flagship fund raised by LYFE Capital, a Shanghai-headquartered healthcare-focused private equity and growth investment firm managing capital across Asia and North America. Closed in approximately the second quarter of 2022 with total commitments of $935 million, Fund IV represents a significant scale-up from the firm's earlier vintages and reflects LYFE Capital's deliberate evolution from a China-focused growth investor into a multi-geography healthcare investment platform with global institutional backing. The fund's 'Dragon' designation is a naming convention LYFE applies to its primary limited partnership vehicles across successive fund generations.
LYFE Capital Fund IV deploys growth equity and private equity capital into pharmaceutical, biotechnology, and life sciences companies, with a particular emphasis on healthcare supply chain assets, manufacturing infrastructure, and businesses positioned to benefit from the global reorganization of Asia's healthcare production base. While China historically accounted for the majority of LYFE's deal activity, Fund IV channels most capital into Asia ex-China markets and the United States — with China representing approximately 10% of the portfolio — reflecting a deliberate rebalancing driven by geopolitical considerations and institutional investor expectations for geographic diversification. The fund pursues control and significant minority positions in established healthcare businesses with documented clinical or commercial progress.
LYFE Capital has established itself as a leading healthcare private equity manager in Greater China and across Asia, with a track record spanning the full pharmaceutical value chain from drug discovery platforms through healthcare services and medical technology. At $935 million, Fund IV is LYFE's largest vehicle to date and attracted commitments from leading institutional investors across Asia, North America, and Europe. The firm's deep sector expertise — spanning biotech, specialty pharma, diagnostics, and healthcare infrastructure — positions Fund IV to capitalize on structural investment opportunities created by regulatory reform, aging demographics, and healthcare manufacturing localization across Asian markets.